Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis - PubMed (original) (raw)
Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis
P Bohanec Grabar et al. Ann Rheum Dis. 2009 Aug.
No abstract available
Similar articles
- The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M. Pawlik A, et al. Pharmacogenomics. 2009 Feb;10(2):303-9. doi: 10.2217/14622416.10.2.303. Pharmacogenomics. 2009. PMID: 19207032 - Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.
O'Doherty C, Schnabl M, Spargo L, Cleland LG, James M, Proudman SM, Wiese MD. O'Doherty C, et al. Pharmacogenomics. 2012 Sep;13(12):1427-34. doi: 10.2217/pgs.12.118. Pharmacogenomics. 2012. PMID: 22966891 - Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.
Soukup T, Dosedel M, Nekvindova J, Toms J, Vlcek J, Pavek P. Soukup T, et al. Clin Exp Rheumatol. 2015 May-Jun;33(3):426-32. Epub 2015 Jan 29. Clin Exp Rheumatol. 2015. PMID: 25664505 Review. - Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis.
Ju JH, Kim SI, Lee JH, Lee SI, Yoo WH, Choe JY, Chung SH, Lee J, Lee YH, Lee SS, Yoon HJ, Yoon CH, Kim HY, Park SH. Ju JH, et al. Arthritis Rheum. 2007 Jun;56(6):2094-6. doi: 10.1002/art.22666. Arthritis Rheum. 2007. PMID: 17530652 No abstract available. - Mechanism of action of leflunomide in rheumatoid arthritis.
Fox RI. Fox RI. J Rheumatol Suppl. 1998 Jul;53:20-6. J Rheumatol Suppl. 1998. PMID: 9666414 Review.
Cited by
- Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum.
Nakafero G, Grainge MJ, Card T, Taal MW, Aithal GP, Zhang W, Doherty M, Fox CP, Mallen CD, Abhishek A. Nakafero G, et al. Rheumatology (Oxford). 2022 Jul 6;61(7):2783-2791. doi: 10.1093/rheumatology/keab790. Rheumatology (Oxford). 2022. PMID: 34718430 Free PMC article. - Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis.
Łączna M, Malinowski D, Paradowska-Gorycka A, Safranow K, Dziedziejko V, Pawlik A. Łączna M, et al. Eur J Clin Pharmacol. 2021 Nov;77(11):1673-1678. doi: 10.1007/s00228-021-03172-3. Epub 2021 Jun 23. Eur J Clin Pharmacol. 2021. PMID: 34160668 Free PMC article. - DHODH inhibition modulates glucose metabolism and circulating GDF15, and improves metabolic balance.
Zhang J, Terán G, Popa M, Madapura H, Ladds MJGW, Lianoudaki D, Grünler J, Arsenian-Henriksson M, McCormack E, Rottenberg ME, Catrina SB, Laín S, Darekar S. Zhang J, et al. iScience. 2021 May 1;24(5):102494. doi: 10.1016/j.isci.2021.102494. eCollection 2021 May 21. iScience. 2021. PMID: 34113829 Free PMC article. - Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis.
Jin R, Liu B, Liu X, Fan Y, Peng W, Huang C, Marcus A, Sica G, Gilbert-Ross M, Liu Y, Zhou W. Jin R, et al. Mol Cancer Ther. 2021 Feb;20(2):274-283. doi: 10.1158/1535-7163.MCT-20-0567. Epub 2020 Dec 8. Mol Cancer Ther. 2021. PMID: 33293343 Free PMC article. - Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis.
Wu X, Sheng X, Sheng R, Lu H, Xu H. Wu X, et al. Front Med. 2019 Aug;13(4):411-419. doi: 10.1007/s11684-018-0659-3. Epub 2019 Jan 12. Front Med. 2019. PMID: 30635780 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical